Thank you very much for your submission to The EMBO Journal. Three scientists provided detailed reports that overall support publication, though conditioned on necessary amendments and clarifications during one round of major revision. As all of the concerns related to rather technical issues and are explicitly stated in the comments, there is not much need for me to repeat them. I kindly ask you to address them as concise as possible before returning a revised version of your manuscript for final scientific assessment. I also have to remind you that it is EMBO_J policy to allow a single round of revisions only and that the ultimate decision depends entirely on content and strength of the revised version that might include assessment from some of the original referees.
Thank you for the opportunity to consider your work for publication. I look forward to your revision. complex in response to ligand stimulation where type II receptors phosphorylate and activate type I receptors. Thus far, it has remained controversial whether TGF-β signaling requires heterodimeric complex or heterotetrameric complex composed of type I and type II receptors.
In this manuscript, the authors generated a TGF-β mutant that induces heterodimeric complex but not heterotetrameric complex, and exploited a variety of biochemical techniques to demonstrate that formation of heterodimeric complex is sufficient for receptor activation. Interestingly, this is not the case in the BMP receptor system. Although the conclusion is not unexpected one, the authors well discuss unsolved questions on receptor complex formation of TGF-β family based on the conclusion of this work.
Experiments are carefully controlled to exclude misinterpretation of the data. Most of the data are obtained in in vitro systems using extracellular domains of the receptors, but they also performed an in vivo cell based assay (Figure 7) . The results obtained are thus clear as well as convincing. In addition, this manuscript is clearly written.
I have a few minor concerns as follows: 1) Page 7, line 13. What is the difference between β3 WT and β3 WW?. This should be explained somewhere in the main text. 2) Page 8, line 2 from the bottom. The authors should briefly explain what TGF-β3 C77S is, preferably also in the legend to Figure 2B where C77S first appears in this manuscript. 3) Figure 4D . The label right to the panels should not be W, but C77S or C77S(W). 4) Figure 7C , left panel. "wt b3" should be "WT". Avoid using different symbols and lines for the same ligands in Figure 7 C and D.
Referee #3 (Remarks to the Author):
The manuscript by Huang et al "TGF-β signaling is mediated by two autonomously functioning TβRI:TβRII pairs" describes a detailed analysis of TGFβ receptor activation mechanism using partially inactivated growth factors. By generating dimeric growth factors in which either one or both of the receptor binding sites are inactivated, the authors can demonstrate that only one receptor pair is sufficient for (reduced) signalling. This is a fine example of detailed analysis of molecular interaction underlaying signalling by transmembrane receptors. The authors have created carefully designed, structure-guided mutants and analysed these biochemically and biophysically to validate their molecular interactions and activities in vitro, and subsequently correlate their molecular properties with in vivo activities.
The major result in this paper is the somewhat surprising finding that a single, functional receptorbinding protomer (see comment below on nomenclature) in the dimeric growth factor is sufficient for activation of the type I receptor by its associated type II receptor. The findings have important implications for the understanding of the molecular mechanism of signalling in TGFβ family (with the small caveat that some of the superfamily members do not bind the two receptors in quite the same way as TGFβs).
Both the growth factors and their receptor ectodomains and associated proteins have complicated, disulfide-linked structures and the authors have done very careful analysis of all the proteins to ensure that they are dealing with homogenious proteins and that the mutants are functionally impaired only in receptor binding. This is essential for a study of this nature, and gives great confidence in the validity of the results. This is the first time that the dimeric nature of TGFβ ligands has been dissected in such detail, and the paradigm that fully active dimer is needed for signalling revised. The findings are novel, and while they might appear at first to contradict the assumption for the need for dimeric growth factor for signalling, the significantly lowered cellular potency of the heterodimeric mutant shows that the proteins described in this study are impaired in full biological sense. One of the emerging themes in TGFβ-like signalling is the combinatorial use of receptor to generate specific signalling outcomes, especially by heterodimeric ligands, and understanding of the way individual halfs of the dimeric ligand can activate its receptors will allow us to gain more insight into the underlying molecular mechanism for this.
The manuscript is well written and clear to follow, and overall technically sound. I would recommend to be published in EMBO J assuming the few minor comments below are addressed satisfactorily.
Technical issues:
1. For most of the TβRII binding data the off-rates appear to be modelled faster than the data suggests, ie. the red curves in Figure 4 A, B and D are all systematically well below the measured curves. If it is not possible to fit the data better, the authors should comment on this issue and offer an explanation for this deviation. I do not think it changes the results in any significant way, especially as the problem appears to be the same for all of the mutants and the wild type protein.
Fitting of data in Supplementary figure S1 A is similarly suboptimal. Fig 4D, (right panel) was fitted to equilibrium data. The data looks decent enough to be fitted to a kinetic model (and if this is not the case, the authors should comment on it), and it appears also that the injections have not quite reached equilibrium at the point where injections were finished. Like before, not a showstopper, but should be commented on.
It was not clear why data in
3. I was not sure if the stoichiometry calculations by SPR and by gel filtration were corrected for molecular weights and absorption coefficients, respectively (Figs 5 A and Table III ). It looks like this is not the case as one would expect more stoichiometric values. The relative changes fully support the authors' conclusions, but it would be good to clarify this small detail.
4. The discussion could be somewhat more thorough and offer more insight into the reasons why we have dimeric growth factors for this family despite the results shown here suggesting a half molecule is enough. Issues such as reduced off-rates on cell surface when bound to multiple receptors and resulting increase in stability of the signalling complex. SPR studies with activin and its receptors for example (Greenwald et al, Mol Cell 2004) have shown how increased receptor density on sensor surface (allowing multiple receptors to bind to single dimeric ligand) results in increased apparent Kd for activin (with two intact binding sites) whereas binding of inhibin (with one binding site) is not affected. The increased Kd for activin is largerly due to reduced off-rate and I see no reason why this would not be the case for TGFbetas as well, despite the differences in receptor interactions. I would see as this effect as the main reason for more than the additive effect the presence of two binding sites has on the biological activity (Fig 7 C and D) and would suggest the discussion to extend a bit further.
5. In the discussion the authors mention 104A distance between typeII receptor C-termini in signalling complex and how this would be too far for TbetaRII-TbetaRII-I signalling. As type II receptor activates the type I receptor, surely the 80A distance that would be relevant for the discussion. (Which is not very different from the 72A distance between the corresponding receptor C-termini in the BMP2 complex)
Minor points:
1. Authors use WT TGFβ3 as a control. What is the difference to WW dimer? Method of preparation, expressed in eukaryotic cells? 2. A minor point on nomenclature: The authors use the term "monomer" for one half of the dimeric growth factor. As an obligate dimer (their C77S mutant notwithstanding!), one half of the molecule should in my view be referred to as protomer and monomer term reserved to a protein which exists in monomeric form.
3. In last paragraph of the intro, the authors say the "residues.... previously shown or implicated to be critical for receptor binding". Please specify which receptor(s).
4. Material and methods say that further details of protein preparation are included in the Supplementary material. This seemed to be missing from copy I received at least.
5. For the sake of clarity, various complexes in the native gels in Figure 3 could This statement was referring to the TβRI:TβRII heterodimers (i.e the interacting TβRI:TβRII heterodimers) that are observed within the structure of the TGF-β receptor complex. The abstract has been revised to clarify this.
p.3 : GDF-3 and -9 are not the only ligands with missing disulfide bonds as mentioned by the authors here.
There is one additional ligand that lacks an interchain disulfide bond (BMP-15) … this has been corrected in the revised text (page 3).
it is not clear what the difference between WT and WW TGFbeta 3 is in these experiments. WT refers to wildtype and WW to two wildtype monomers in the dimer. Please clarify!
TGF-β3 WT and TGF-β3 WW both refer to E. coli recombinant wild type TGF-β3 … the difference is the manner in which they were obtained. TGF-β3 WT was isolated by HPLC from a folding reaction in which only the wild type (W) monomer was added. TGF-β3 WW was isolated by HPLC from a folding reaction in which the wild type (W) and substituted (D) monomers were added (in a 1:1 molar ratio).
The comparison between TGF-β3 WT and WW was done for representative purified component and cell-based assays, but not for all (so as to avoid redundancy after it became apparent that there was no difference between TGF-β3 WT and TGF-β3 WW, as presumed).
We have added an explicit statement describing the difference between TGF-β3 WT and TGF-β3 WW in the main text, as requested (page 7). Figure 3A , where TGF-β3 WW, WT, and DD, which all have essentially the same molecular size (Fig. 2b) , are shown to have markedly different mobilities.
This is the reason that molecular size markers are not normally included on native gels. The standard approach for "referencing" native gels, especially as they are applied to studying the formation of protein complexes, is to simply run the constituent proteins alone (see as examples Zuniga, et al (2005 ) J. Mol. Biol. 354:1052 -1068 . This has been done for all the proteins studied in Fig. 3A (leftmost panel).
Regarding the difference between TGF-β3 WT and WW: This has already been addressed under in response to the Referee 1's third query (above).
Regarding the request to label the bands: The bands have been labeled (both in panel A and B).
Regarding the smear for TGF-β3: We think this might be related to the unusual migration also observed for TGF-β3 WD on ion-exchange columns in the presence of urea (Fig 6D) . We have added a note to this effect in the legend for Figure 3 .
5. Fig. 3B: Regarding molecular weight markers: This is also a native gel and thus we have not run size markers (for the same reason given above).
Regarding the experimental design: The objective of this experiment was to determine which of the isolated dimers (TGF-β3 WW, WD, and DD) were capable of binding and recruiting TβRI, and for those that do, with what stoichiometry. This was done by titrating a fixed amount of TβΡΙ with increasing amounts of the TGF-β:TβRII complex (where TGF-β and TβRII were combined in a 1:2 molar ratio). This design parallels that used in Fig. 3A to assess binding of the isolated dimers (TGF-β3 WW, WD, and DD) to ΤβΡΙΙ (where the amount of TβRII was fixed and increasing amounts of TGF-β was added).
The referee suggests that the experiment in Fig. 3b be done in the opposite manner … that is by keeping the amount of TGF-β:TβRII complex fixed and by adding increasing amounts of TβΡI. This design is certainly feasible, but in practice, has no particular advantage to that used; moreover, this design would differ from that used in panel A.
Regarding the ratios: The 2:4:2 ratio is the same as a 1:2:1 ratio. The referee is presumably requesting a clarification of this point in reference to the titration of TGF-β3 WD, where the 2 equivalents of TβRI are fully titrated when 2 equivalents of TGF-β3 WD and 4 equivalents of TβRII are added.
The referee logically assumes that TGF-β3 WD forms a 2:4:2 (or 1:2:1) TGF-β3 WD:TβRII:TβRI complex based on this (as indicated by Referee 1's ninth query below).
This, however, is not correct as TβRII was always added in a 2:1 molar ratio relative to TGF-β, whether it was required or not. ΤβΡΙΙ was added in this manner for two reasons: (1) To ensure that the binding of TβRI was not in any way limited by TβRII (since binding of TβRI is absolutely dependent upon TβRII); (2) To ensure that all of the titrations were done in the same manner, with only one variable (the nature of the TGF-β ligand added).
The results presented in Fig. 1 suggest that the 2:1 TβRII:TGF-β ratio was required for TGF-β3 WT and WW, but not TGF-β3 WD or DD; further consistent with this, no excess TβRII is present when TGF-β3 WT (or TGF-β3 WW), TβRII, and TβRI are combined in a 2:4:2 (or 1:2:1) ratio, but there is when TGF-β3 WD, TβRII, and TβRI are combined in this ratio. Thus, even though qualitative, the native gel results indicate that TGF-β3 WD binds and assembles a 1:1:1 TGF-β3:TβRII:TβRI complex, not a 1:2:1.
To clarify the presentation of Fig 3b , the text has been modified to emphasize that a) TβRII was always added in a 2:1 molar ratio relative to TGF-β, whether it was needed or not, and b) that TβRII was in excess when TGF-β3 WD, TβRII, and TβRI were combined in a ratio of 2:4:2 (or 1:2:1) (page 8). (Fig. 4) The ligands were biotinylated in solution in the presence of the receptors to decrease the likelihood that residues within the binding interface are modified. This is important for SPR experiments as it increases the likelihood that the immobilized ligand is capable of binding the receptors with wildtype like affinity (not reduced affinity, due to covalent modification of residues that partially or fully occlude the binding sites).
p.8: it is not clear why for the SPR experiments described here, the ligands were biotinylated in the presence of the exctracellular domains of the receptors. This way it might be that the ligand:receptors complex is captured at the streptavidin surface via biotinylated residues from the receptors and not the ligand. If then affinities to receptors are measured
This, however, will not cause the problems the Referee envisions as the biotinylated ligand were fully separated away from the receptors using HPLC once the biotinylation reaction was complete. Thus, the ligand alone is captured on the streptavidin surface, not the complex.
The main text specifically mentioned that the ligand was 'isolated' after it was biotinylated; to further clarify this, the main text has been expanded to further emphasize that the receptors were removed prior to immobilization of the ligand on the SPR sensor surface (page 8); the details of how this was accomplished is described in Material and Methods (pages 19-20).
p.8 (second lane from bottom): TGFbeta3-C77S is mentioned here for the first time; please describe here briefly.
This is a variant of TGF-β3 in which the cysteine residue that forms the inter-chain disulfide, Cys77, is substituted with serine. This protein has been previously studied (Ilangovan, et al (2004) J. Biomol. NMR, 29:103-104; Zuniga, et al (2005) J. Mol. Biol, 354:0152-1068) and is covalently monomeric (as shown in Fig. 2B ). This protein is more explicitly described in the revised text (page 7).
Please explain, why here the biotinylation was done differently to the experiments in figure 4.
The Referee is presumably referring to the SPR experiment in which we studied the binding of BGe, TβRII, and TβRI to TGF-β3 WW, WD, and DD (Supplementary Material, Fig. 2 ). The ligands in this case were not in fact biotinylated … instead, the ligands were coupled directly using carbodiimide chemistry (commonly referred to as 'amine coupling').
The reason we chose to immobilize the ligands in this manner is to ensure that they were all modified in the same manner. This was not necessarily so with the "receptor-protected" ligands used in the SPR experiment presented in Figure 4 since TGF-β3 WD and DD will be more susceptible to covalent modification (with a biotinylation reageant) compared to TGF-β3 WW (since they don't bind the full complement of receptors, as does TGF-β3 WW). This "differential" modification would be undesirable since it would then be unclear as to whether the differences in receptor binding stochiometries are a consequence of the differences in the ligands themselves or whether its due to differences in the way that they were covalently modified. The text has been modified to explain this important point (page 10). Figure 3B , which suggested a 1:2:1 ratio for WD, while here a 1:1:1 ratio was determined.
page 11 and figure 6: how do you explain the inconsistancy between the results here (HPLC) and in
The native gel results presented in Fig. 3B , though qualitative, are consistent with TGF-β3 WD forming a 1:1:1 TGF-β3 WD:TβRII:TβRI complex, not a 1:2:1, as explained above (fifth point). Thus, the native gel results (Fig. 3B ) are not inconsistent with the HPLC results (Fig. 6 ). Figure 7B (30min) so much weaker when compared to 1pM WD in Fig. 7A ?
p11 and 12 and figures 7A and B: why are the signals obtained with 40pM WD in
This discrepancy was caused by a mistake in the original figure. The concentrations of the TGF-β ligands used in panel A were 1 and 2 ng/mL (not 1 and 2 pM as indicated). 1 and 2 ng/mL TGF-β correspond to 40 and 80 pM TGF-β, so in fact, essentially the same concentrations were used in panels A and B. The figure has been corrected accordingly.
Please give a better explanation, why WD shows less phosphorylation of Smad3 when
compared to the WT ligand, while reading CAGA12 luciferase no differences are observed (refers to p. 14).
As explained, the level of pSmad provides a direct measure of receptor activity, whereas both the reporter-gene and growth inhibition assays provide indirect measures (since there are many intervening processes between induction of pSmad2, 3 and the induction of luciferase or inhibition of cell growth). As such, there is no reason to expect that a four-fold difference in the level of pSmad in the Smad phosphorylation assay will also lead to a four-fold difference in reporter gene activity.
Additionally, it is worth noting that Amatayakul-Chantler, et al (J. Biol. Chem, 269: 27687-27691) previously showed that the reporter gene assay is inherently less sensitive to reductions in receptor activity (i.e. induction of pSmad2, 3) compared to the growth inhibition assay. According to their data, monomeric TGF-β1 (TGF-β1 C77S) was reduced in its potency 8-fold compared to dimeric (WT) TGF-β1 in a reportor gene assay, but more than 100-fold in a growth inhibition. As shown by the data presented in Table IV , similar results are obtained in this study with TGF-β3 C77S (9-fold reduction in potency in the reporter gene assay compared to wild type, but 43-fold in the growth inhibition assay). As such, its not surprising that TGF-β3 WD, which is reduced in its growth inhibitory activity by no more than 2-fold, exhibits no detectable difference in its reporter gene activity.
An explanation to this effect has been added to the revised text (pages 15 -16).
12. Figure 9 : in both cases (TGFbeta and BMP receptors) This point was also raised by Referee 1 and an explanation as to the difference has been added to the main text as requested (page 7). Figure 2B where C77S first appears in this manuscript.
2) Page 8, line 2 from the bottom. The authors should briefly explain what TGF-β3 C77S is, preferably also in the legend to
This point was also raised by Referee 1 and an explanation as to the difference has been added to the main text as requested (page 7).
3) Figure 4D . The label right to the panels should not be W, but C77S or C77S(W) .
This has been corrected. Figure 7C , left panel. "wt b3" should be "WT". Avoid using different symbols and lines for the same ligands in Figure 7 C and D.
4)
The first point was also raised by Referee 1 and has been corrected; Regarding the second point, consistent symbols and lines are now used for the reporter gene and growth inhibition data (Figures 7 C, D) as requested.
Referee 3: figure S1 A is similarly suboptimal.
For most of the TβRII binding data the off-rates appear to be modelled faster than the data suggests, ie. the red curves in Figure 4 A, B and D are all systematically well below the measured curves. If it is not possible to fit the data better, the authors should comment on this issue and offer an explanation for this deviation. I do not think it changes the results in any significant way, especially as the problem appears to be the same for all of the mutants and the wild type protein. Fitting of data in Supplementary
We also noticed this systematic deviation, but were not able fit the data any better to eliminate it. We believe the deviation arises either as a consequence of some residual minor heterogeneity in the way that the ligand was coupled to the sensor chip or suppression of the off-rate due to rebinding or interactions with the dextran matrix. We did not mention it in the text, but the Kds obtained by equilibrium analysis (which would not be susceptible to this same deviation) are essentially indistinguishable from those obtained by kinetic analysis, as summarized below: Hence, the systematic deviation of kinetic fits has only a minor effect on the Kds and does not in any way change our conclusions. A statement to this effect has been added to the revised text (page 9).
Ligand
We also think its important to mention that the SPR data shown, while not perfectly ideal (according to a 1:1 binding model), is far better than that obtained with ligand coupled directly to the dextran surface (using 'amine coupling'). We believe the underlying basis for this is the increased homogeneity of the ligand on the sensor surface. Fig 4D, This data cannot be satisfactorily fit to a simple (1:1) kinetic model. This is likely because the TβRI
It was not clear why data in

